According to a press release, preclinical data on adipose-derived mesenchymal stem cells—presented by Nicole Ehrhart, professor of Surgical Oncology at the Colorado State University (CSU) Flint Animal Cancer Center (Fort Collins, USA), at the State of Spine Surgery 13th Annual Symposium and at the Korean American Spine Society meeting—showed bone formation in all study subjects.
Ehrhart’s preclinical study, entitled “Adipose-Derived Mesenchymal Stromal Cells Seeded on Demineralized Bone Matrix Persist and Differentiate When Implanted in a Critical-Sized Rat Femur Defect” showed bone formation within a critical-sized defect in all study subjects. Stem cells were detected for up to 84 days in areas of new formation and differentiated within the bony repair tissue.
The press release—issued by AlloSource—states that the research used similar technology to the company’s AlloStem cellular bone allograft proprietary, patented process. AlloStem is partially demineralised allograft bone combined with adipose-derived mesenchymal stem cells. Suitable for general bone grafting applications, AlloStem is similar to autograft bone, according to the release, because it can provide osteoconduction, osteoinduction and osteogenesis.
“Research is an important part of allograft development, and the cellular validation from this study tells a story about AlloStem and its ability to help heal patients,” says AlloSource’s vice president of Strategy, Development and Growth, Peter Stevens. “We look forward to our continued work with Ehrhart and CSU to maximise the gift of tissue donation.”
Ehrhart says, “This work is another example of how…AlloStem promotes bone formation in challenging bone healing environments.”
Ehrhart’s study has also been accepted for publication in Journal of Biomaterials and Tissue Engineering.